The patent for Axid, US6930119, is set to expire on July 17, 2022. Following this date, generic versions of Axid may become available, assuming there are no additional patents or exclusivities protecting this drug.
Axid, with its active ingredient nizatidine, is used to decrease the amount of acid produced in the stomach. This acid reducer is effective in treating and preventing ulcers in the stomach and intestines. It is also used to treat conditions where the stomach produces too much acid.
Axid's last standing patent, US6930119, is set to expire on July 17, 2022. Following the patent expiry, we could expect the release of Axid generic. Below are the details of the patent: